Article

Dispersive OVD gains FDA approval

The FDA has approved a dispersive ophthalmic viscosurgical device (OVD) (Healon EndoCoat OVD, Abbott Medical Optics) for use as a surgical aid in cataract extraction and IOL implantation.

Abbott Park, IL-The FDA has approved a dispersive ophthalmic viscosurgical device (OVD) (Healon EndoCoat OVD, Abbott Medical Optics) for use as a surgical aid in cataract extraction and IOL implantation.

The OVD is injected into a patient’s eye to protect and coat the eye during surgery. It is designed to reduce trauma to the inside layer of the cornea and other surrounding tissues.

“A dispersive OVD is highly desirable at the beginning of the cataract removal process to help protect the eye from nuclear particles and ultrasonic energy,” said Roger F. Steinert, MD, the Irving H. Leopold Professor and Chair, and director of the Gavin Herbert Eye Institute, at the University of California, Irvine. “[This new dispersive viscosurgical device] is ideal for this protective barrier. It has outstanding clarity and does not require refrigeration, which reduces surgicenter storage costs and improves ease of use compared with a cold syringe.”

Dispersive OVDs are expected to account for approximately 50% of the total OVD market in 2012, according to the ophthalmic research firm Market Scope.

The product has begun to be shipped in the United States.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.